

CITATION REPORT

List of articles citing

Trends in the prescription of novel oral anticoagulants
in UK primary care

DOI: 10.1111/bcp.13299

British Journal of Clinical Pharmacology, 2017, 83, 2096-2106.

Source: <https://exaly.com/paper-pdf/66634876/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
190	Trends in the prescription of novel oral anticoagulants in UK primary care. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 2096-2106	3.8	163
189	Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. 2017 , 26, 1546-1554		13
188	Challenges for learning health systems in the NHS. Case study: electronic health records in cardiology. 2017 , 4, 193-197		2
187	Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. 2017 , 5, 322		42
186	Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. 2018 , 71, 1105-1113		28
185	Impact of pre-admission treatment with non-vitamin K oral anticoagulants on stroke severity in patients with acute ischemic stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 529-535	5.1	10
184	Should surgery be delayed in patients taking direct oral anticoagulants who suffer a hip fracture? A retrospective, case-controlled observational study at a UK major trauma centre. <i>BMJ Open</i> , 2018 , 8, e020625		39
183	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. <i>BMJ Open</i> , 2018 , 8, e018180	3	31
182	In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. 2018 , 365, 519-525		16
181	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 111-118	6.4	23
180	Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 590-601	3.8	8
179	Deprivation and inequalities lead to worse outcomes with dabigatran etexilate. 2018 , 10, 303-311		3
178	Practice variation in the use of tests in UK primary care: a retrospective analysis of 16 million tests performed over 3.3 million patient years in 2015/16. <i>BMC Medicine</i> , 2018 , 16, 229	11.4	11
177	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. 2018 , 14, 1057-1069		21
176	Complications Arising From Perioperative Anticoagulant/Antiplatelet Therapy in Major Colorectal and Abdominal Wall Surgery. 2018 , 61, 1306-1315		3
175	Testing and monitoring direct oral anticoagulants. 2018 , 132, 2009-2015		39
174	Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. 2018 , 7, 1063-1071		4

173	Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study. 2018 , 68, e551-e558		6
172	Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series. 2018 , 12, 138		13
171	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). 2018 , 39, 3973-3979		79
170	A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2692-2703	3.8	13
169	Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. 2018 , 14, 13-21		11
168	When to Resume Direct Oral Anticoagulants Following Gastrointestinal Bleeding. 2018 , 16, 1870-1871		
167	Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. 2019 , 216, 117-124		5
166	Prescribers' views and experiences of using direct acting oral anticoagulants in the management of nonvalvular atrial fibrillation: A survey in remote and rural Scotland. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2414-2422	3.8	2
165	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2524-2539	3.8	29
164	A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove. 2019 , 187, 377-385		22
163	Safe prescribing in general dental practice – challenges and solutions. 2019 , 46, 828-835		
162	Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the Veterans Health Administration. 2019 , 8, e012646		15
161	Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. <i>PLoS ONE</i> , 2019 , 14, e0221500	3.7	9
160	Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants. 2019 , 55,		5
159	Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. 2019 , 8, 165-178		13
158	Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. 2019 , 9,		37
157	Patterns in anticoagulant utilization in the Czech Republic during 2007-2017. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 305-311	5.1	5
156	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. 2019 , 18, 187-209		15

155	Association of stroke and bleed events in non-valvular atrial fibrillation patients with direct oral anticoagulant prescriptions in NHS England between 2013 and 2016. <i>PLoS ONE</i> , 2019 , 14, e0218878	3.7	3
154	Patients on NOACs in the Emergency Room. 2019 , 19, 40		2
153	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. 2019 , 37, 100579		8
152	Hemorrhagic Cardiac Tamponade Associated with Apixaban: A Case Report and Systematic Review of Literature. 2019 , 20, 15-20		4
151	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). 2019 , 17, 7		7
150	Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	25
149	Head injury in the elderly - an overview for the physician. 2019 , 19, 177-184		5
148	Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use. 2019 , 39, 401-405		1
147	Use of oral anticoagulants in older people with atrial fibrillation in UK general practice: protocol for a cohort study using the Clinical Practice Research Datalink (CPRD) database. <i>BMJ Open</i> , 2019 , 9, e032646		2
146	Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. <i>BMJ Open</i> , 2019 , 9, e031341	3	21
145	Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. <i>BMJ Open</i> , 2019 , 9, e031342	3	9
144	Should Adults With Mild Head Injury Who Are Receiving Direct Oral Anticoagulants Undergo Computed Tomography Scanning? A Systematic Review. 2019 , 73, 66-75		10
143	Outcomes of intraparenchymal hemorrhage after direct oral anticoagulant or vitamin K antagonist therapy: A systematic review and meta-analysis. 2019 , 62, 188-194		1
142	Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials. 2019 , 42, 198-205		5
141	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13285	2.9	7
140	The risk of delayed intracranial hemorrhage with direct acting oral anticoagulants after trauma: A two-center study. 2019 , 217, 1051-1054		14
139	Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin. 2019 , 9, 120-124		4
138	Incidence, mortality and bleeding rates associated with pulmonary embolism in England between 1997 and 2015. 2019 , 277, 229-234		10

137	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. 2020 , 31, 43-47		1
136	Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. 2020 , 20, 259-267		1
135	Do anticoagulants affect outcomes of hip fracture surgery? A cross-sectional analysis. 2020 , 140, 171-176		14
134	Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 160, 1222-1231	1.5	11
133	Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. <i>Heart</i> , 2020 , 106, 119-126	5.1	33
132	In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. 2020 , 34, 109-119		12
131	Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies. 2020 , 109, 465-475		6
130	A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 114-122	15.4	45
129	Impact of Anticoagulation on Mortality and Resource Utilization Among Critically Ill Patients With Major Bleeding. 2020 , 48, 515-524		6
128	Acute ICH in patients identified as being treated with either warfarin or direct-acting oral anticoagulant agents (DOACs) from a radiology perspective; a cross-sectional observational of 2359 emergency CT head studies. 2020 , 75, 271-277		2
127	Consequences of pre-injury utilization of direct oral anticoagulants in patients with traumatic brain injury: A systematic review and meta-analysis. 2020 , 88, 186-194		10
126	National Physician Survey for Nonvalvular Atrial Fibrillation (NVAf) Anticoagulation Comparing Knowledge, Attitudes and Practice of Cardiologist to PCPs. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020 , 26, 1076029620952550	3.3	1
125	Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants. 2020 , 8, e00603		7
124	Haemorrhagic nasal polyp mimicking melanoma in an 83-year-old on rivaroxaban. 2020 , 13,		0
123	Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. 2020 , 4, 4208-4216		3
122	Prescribers' perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation. 2020 , 18, 1936		
121	Anticoagulation decisions in elderly patients with stroke. 2020 , 176, 692-700		
120	Risk of significant traumatic brain injury in adults with minor head injury taking direct oral anticoagulants: a cohort study and updated meta-analysis. 2020 , 37, 666-673		7

119	Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 986-998	5.3	3
118	Patients Taking Direct Oral Anticoagulants (DOAC) Undergoing Oral Surgery: A Review of the Literature and a Proposal of a Peri-Operative Management Protocol. 2020 , 8,		3
117	Time Trends in Intracerebral Hemorrhage Associated with Oral Anticoagulation and Its Risks Factors in Spain from 2008 to 2015. 2021 , 84, 16-21		1
116	Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry. 2020 , 16, 469-480		2
115	Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort. 2020 , 13, e006058		10
114	Trends in oral anticoagulant prescribing in individuals with type 2 diabetes mellitus: a population-based study in the UK. <i>BMJ Open</i> , 2020 , 10, e034573	3	9
113	Hand and wrist surgery on anticoagulants and antiplatelets: A systematic review and meta-analysis. 2020 , 73, 1413-1423		1
112	Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2296-2307	15.4	20
111	Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use. 2020 , 13, e005894		5
110	Use of oral anticoagulation therapy in the first 3 months after the diagnosis of atrial fibrillation in Israel: A population-based study. 2020 , 31, 1356-1363		2
109	Genotype-guided warfarin therapy: Still of only questionable value two decades on. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020 , 45, 547-560	2.2	8
108	Budget impacts associated with improving diagnosis and treatment of atrial fibrillation in high-risk stroke patients. 2020 , 9, 253-262		0
107	Perioperative management of women on oral anticoagulants and antiplatelet agents undergoing gynaecological procedures. 2020 , 22, 131-136		1
106	Management of venous thromboembolism in patients experiencing direct oral anticoagulant treatment failure: a single-center review of practice and outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 441-445	5.1	2
105	Prevalence of Intracranial Injury in Adult Patients With Blunt Head Trauma With and Without Anticoagulant or Antiplatelet Use. 2020 , 75, 354-364		10
104	Trends in anticoagulant prescribing: a review of local policies in English primary care. 2020 , 20, 279		39
103	A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation. 2020 , 42, 474-481		
102	Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation. 2020 , 9, 2048004020915406		2

101	How should we manage hip fracture patients on direct oral anticoagulants?. 2021 , 26, 22-23		3
100	Patterns and factors influencing oral anticoagulant prescription in people with atrial fibrillation and dementia: Results from UK primary care. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1056-1068	3.8	1
99	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban-A European comparative drug utilization study. 2021 , 128, 440-454		1
98	The effect of anticoagulants on oral squamous cell carcinoma: A systematic review. 2021 , 50, 118-121		0
97	Anticoagulant selection in relation to the SAME-TTR score in patients with atrial fibrillation: The GLORIA-AF registry. 2021 , 62, 152-157		1
96	Clinical and budget impacts of changes in oral anticoagulation prescribing for atrial fibrillation. <i>Heart</i> , 2021 , 107, 47-53	5.1	8
95	Adherence to dabigatran and the influence of dabigatran-induced gastrointestinal discomfort in the real-world practice. 2021 , 323, 77-82		0
94	Use of non-vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database. 2021 , 30, 426-434		2
93	Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 58-69	7	5
92	Should patients treated with oral anti-coagulants be operated on within 48h of hip fracture?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 1132-1137	5.1	3
91	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. 2021 , 16, 591-599		3
90	High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Case-Cohort Study. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 70-75		1
89	Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 11-19	6.4	15
88	Schädel-Hirn-Trauma bei älteren Patienten. 2021 , 121-142		
87	Investigation of the Optimal Dose of PCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021 , 27, 10760296211021156	3.3	0
86	Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1061-1070	4	3
85	Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review. <i>BMJ Open</i> , 2021 , 11, e042024	3	2
84	Evaluating equality in prescribing Novel Oral Anticoagulants (NOACs) in England: The protocol of a Bayesian small area analysis. <i>PLoS ONE</i> , 2021 , 16, e0246253	3.7	

83	Hospital admissions for stroke and bleeding in Hounslow following a quality improvement initiative. <i>Open Heart</i> , 2021 , 8,	3	1
82	Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data. <i>Seminars in Thrombosis and Hemostasis</i> , 2021 , 47, 150-160	5.3	3
81	Anticoagulation trends in adults aged 65 and over with atrial fibrillation; a cohort study.		1
80	Nonvitamin K oral anticoagulants in cardiac surgery: What cardiothoracic surgeons need to know 2.0. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 ,	1.5	2
79	Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 646-653	5.1	8
78	Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021 , 12, 586370	5.6	4
77	Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 62-72	0.5	
76	Safe prescribing of direct oral anticoagulants for non-valvular AF. <i>The Prescriber</i> , 2021 , 32, 26-30	0.4	
75	Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results. <i>Meditsinskiy Sovet</i> , 2021 , 41-46	0.4	
74	Dabigatran-Induced Nephropathy and Gastrointestinal Bleeding and Its Successful Treatment with Idarucizumab: A Case Report. <i>Hospital Pharmacy</i> , 001857872110163	1.1	0
73	Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
72	Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation. <i>Patient Preference and Adherence</i> , 2021 , 15, 953-966	2.4	1
71	Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
70	Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns. <i>Clinical Therapeutics</i> , 2021 , 43, 1179-1190.e3	3.5	0
69	Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	
68	The association between increasing oral anticoagulant prescribing and atrial fibrillation related stroke in Ireland. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	0
67	Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations. <i>Pharmacogenomics Journal</i> , 2021 , 21, 625-637	3.5	1
66	Bleeding and Clotting Disorders. 2021 , 665-704		

65	Combining Clinical and Polygenic Risk Improves Stroke Prediction Among Individuals With Atrial Fibrillation. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003168	5.2	3
64	Trends in the pharmacological management of atrial fibrillation in UK general practice 2008-2018. <i>Heart</i> , 2021 ,	5.1	0
63	Neurologists' Attitudes and options for anticoagulation therapy in central China. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14305	2.9	0
62	Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention study. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1919-1926	2.8	
61	Challenges in the PREHOSPITAL emergency management of geriatric trauma patients - a scoping review. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2021 , 29, 100	3.6	2
60	Use of Primary Care Data in Research and Pharmacovigilance: Eight Scenarios Where Prescription Data are Absent. <i>Drug Safety</i> , 2021 , 44, 1033-1040	5.1	1
59	Prescription patterns of direct oral anticoagulants and concomitant use of interacting medications in the Netherlands. <i>Netherlands Heart Journal</i> , 2021 , 29, 451-459	2.2	1
58	Changes of recommended anticoagulation therapy in patients with atrial fibrillation and high thrombotic risk: long-term follow-up data from two hospital centers. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 857-863	2.5	0
57	Prescribing of direct oral anticoagulants and warfarin to older people with atrial fibrillation in UK general practice: a cohort study. <i>BMC Medicine</i> , 2021 , 19, 189	11.4	1
56	Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study. <i>Open Heart</i> , 2021 , 8,	3	6
55	Anti-thrombotics and their impact on inpatient epistaxis management: a tertiary centre experience. <i>Irish Journal of Medical Science</i> , 2021 , 1	1.9	
54	Experiencing a virtual patient to practice patient counselling skills.. <i>Currents in Pharmacy Teaching and Learning</i> , 2021 , 13, 1593-1601	1.5	0
53	Trends in the incidence and mortality of intracerebral hemorrhage, and the associated risk factors, in Denmark from 2004 to 2017. <i>European Journal of Neurology</i> , 2022 , 29, 168-177	6	0
52	The Risk of Bleeding Complications in Intra-Articular Injections and Arthrocentesis in Patients on Novel Oral Anticoagulants: A Systematic Review. <i>Cureus</i> , 2021 , 13, e17755	1.2	1
51	Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
50	A drug utilization study of oral anticoagulants in five representative cities of China between 2015 and 2019. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 ,	2.2	0
49	Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021 , 26, 656-664	2.6	
48	Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	

47	Medication errors associated with direct-acting oral anticoagulants: analysis of data from national pharmacovigilance and local incidents reporting databases. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021 , 14, 81	3.2	1
46	Management of patients with hip fracture receiving anticoagulation: What are we doing in Canada?. <i>Canadian Journal of Surgery</i> , 2021 , 64, E510-E515	2	0
45	A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study. <i>Thrombosis Research</i> , 2021 , 206, 76-83	8.2	1
44	Epidemiology of Venous Thromboembolism and Treatment Pattern of Oral Anticoagulation in Korea, 2009-2016: a Nationwide Study Based on the National Health Insurance Service Database. <i>Journal of Cardiovascular Imaging</i> , 2021 , 29, 265-278	1.3	3
43	Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel. <i>Scientific Reports</i> , 2021 , 11, 2634	4.9	2
42	Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants. <i>Hemato</i> , 2021 , 2, 64-78	0.2	0
41	[Use of direct-acting oral anticoagulants in Primary Care in Spain. Positioning statement by SEMERGEN on the current situation]. <i>Semergen</i> , 2019 , 45, 413-429	1.9	10
40	Combining clinical and polygenic risk improves stroke prediction among individuals with atrial fibrillation.		2
39	Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2003-2017	15.4	16
38	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 299-306	0.4	1
37	A SIX YEAR DRUG UTILIZATION STUDY IN A TERTIARY HEALTHCARE SYSTEM: EMERGENCE OF NEWER ORAL ANTICOAGULANTS. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2019 , 6, 676-679	0	1
36	Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends. <i>BMC Cardiovascular Disorders</i> , 2021 , 21, 493	2.3	0
35	"I just didn't want to trust it at all": Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin. <i>Journal of Evaluation in Clinical Practice</i> , 2021 ,	2.5	
34	2018 EHRA Practical Guide, Rationale, History and Experience. <i>European Journal of Arrhythmia & Electrophysiology</i> , 2018 , 4, 43	0.3	
33	Remedial dosing recommendation for delayed or missed rivaroxaban doses for patients with non-valvular atrial fibrillation based on Monte Carlo simulation.		
32	New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants. <i>Rational Pharmacotherapy in Cardiology</i> , 2020 , 16, 670-677	0.5	0
31	Research Trends in Anticoagulation Therapy over the Last 25 Years. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 919-931	5.3	1
30	Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2021 , 1	2.8	3

29	Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants. <i>International Journal of Arrhythmia</i> , 2022 , 23,	2.4	0
28	Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data.. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	
27	Acute haemorrhage rate in 28,000 Out-of-Hours CT heads.. <i>British Journal of Radiology</i> , 2021 , 20210580	3.4	
26	Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-9	2.9	3
25	Patients and clinicians' perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis.. <i>BMC Family Practice</i> , 2021 , 22, 254	2.6	0
24	Timing of Surgery for Hip Fracture in Patients on Direct Oral Anti-coagulants: A Population-Based Cohort Study.. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2022 , 13, 21514593221088405	2	
23	Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus.. <i>Thrombosis and Haemostasis</i> , 2022 ,	7	0
22	Safety and efficacy of direct oral anticoagulants (DOAC) in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study.. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	1
21	Management of Coagulopathy in Bleeding Patients.. <i>Journal of Clinical Medicine</i> , 2021 , 11,	5.1	3
20	[Changes in Prescription Patterns of Oral Anticoagulants in Family Practices after Marketing Approval of Direct Oral Anticoagulants].. <i>Gesundheitswesen</i> , 2022 ,	0.5	
19	New oral anticoagulants in nonvalvular atrial fibrillation. 2022 , 1, 22-27		
18	Management of Haemarthrosis in Patients On Oral Anticoagulants.. <i>Geriatric Orthopaedic Surgery and Rehabilitation</i> , 2022 , 13, 21514593221076966	2	0
17	Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9,	5.4	3
16	Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care. <i>BMJ Open</i> , 2022 , 12, e059311	3	
15	Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. <i>PLoS Medicine</i> , 2022 , 19, e1004003	11.6	1
14	APIXABAN® DOZA BAĞI ANTİANJİYOTİK POTANSİYELİ Deneyisel bir bakış <i>Acta Medica Alanya</i> ,		
13	Prescribing direct-acting oral anticoagulants [Mind the evidence gap. <i>British Journal of Clinical Pharmacology</i> ,	3.8	
12	Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus.		2

- 11 Analysis of the trend in Oral Anticoagulation Overdose from 2010 to 2020 Ireland. ○
- 10 Assessment of knowledge and practice of cardiovascular nurses regarding warfarin. **2022**, 11, 270 ○
- 9 Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known. ○
- 8 Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study. ○
- 7 Epidemiology and Treatment Patterns of Venous Thromboembolism: an Observational Study of Nationwide Time-Series Trends in Japan. ○
- 6 Reduction of Ischemic Stroke Associated Disability in the Population: A State-Wide Stroke Registry Analysis over a Decade. **2022**, 11, 6942 ○
- 5 Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands. ○
- 4 The Effect of Warfarin Use on Postoperative Outcomes after Femoral Neck Surgery. **2023**, 12, 1307 ○
- 3 Efficacy of PERT Care: Evidence. **2023**, 1-29 1
- 2 Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019. **2023**, 83, 315-340 ○
- 1 Efficacy of PERT Care: Evidence. **2023**, 1-29 ○